Oxford Pharmascience Group (OXP)

 

Latest News

Holding(s) in Company

RNS Number: 2665X Oxford Pharmascience Group PLC 22 November 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: O...

Holding(s) in Company

RNS Number: 2224X Oxford Pharmascience Group PLC 22 November 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ...

Second Price Monitoring Extn

RNS Number: 0213X Oxford Pharmascience Group PLC 20 November 2017 Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension this security would still have executed more than a...

Price Monitoring Extension

RNS Number: 0203X Oxford Pharmascience Group PLC 20 November 2017 Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders entered in an individual security's auction call b...

All News

DateHeadlineSource
22-11-17Holding(s) in CompanyRNS
22-11-17Holding(s) in CompanyRNS
20-11-17Second Price Monitoring ExtnRNS
20-11-17Price Monitoring ExtensionRNS
20-11-17MPA Advice on OXPzeroT Ibuprofen OTC OpportunityRNS
10-11-17Oxford Pharmascience proposes demergerStockMarketWire
10-11-17Announcement of demergerRNS
02-10-17OXP receives MHRA advice on OXPzeroStockMarketWire
02-10-17MHRA Advice on OXPzeroT Ibuprofen OTC OpportunityRNS
25-09-17Interim ResultsRNS
19-06-17All resolutions passed at AGM of Oxford PharmascienceStockMarketWire
19-06-17Result of AGMRNS
08-06-17Further Update re: OXPzero Ibuprofen ProgrammesRNS
09-05-17Update regarding OXPzeroTM Ibuprofen ProgrammesRNS
31-03-17Miners drag on FTSE as commodity prices fall StockMarketWire
31-03-17Second Price Monitoring ExtnRNS
31-03-17FTSE falls on miners, financials as Old Mutual suffersStockMarketWire
31-03-17Price Monitoring ExtensionRNS
31-03-17Oxford Pharmascience disappointed with FDA feedbackStockMarketWire
31-03-17FDA Feedback on OXPzeroT Ibuprofen Rx ProgrammeRNS
10-03-17Oxford Pharmascience narrows FY pretax lossStockMarketWire
10-03-17Final ResultsRNS
07-03-17Notice of ResultsRNS
23-02-17Company UpdateRNS
25-01-17Oxford Pharmascience - Company updateBRR Media
17-01-17Oxford Pharmascience issues company updateStockMarketWire
17-01-17Company UpdateRNS
09-11-16R&D UpdateRNS
19-10-16Here's what Neil Woodford is buying and sellingInteractive Investor
13-09-16Oxford Pharmascience - Interim results 2016BRR Media
07-09-16Interim results for the 6 months to 30 June 2016RNS
21-07-16Oxford Pharmascience downgraded by BeaufortStockMarketWire
21-07-16Broker Forecast - Beaufort Securities issues a broker note on Oxford Pharmascience Group PLCStockMarketWire
20-07-16FTSE rises on pharmas, financials as miners ebbStockMarketWire
20-07-16Commercial Update & Directorate ChangeRNS
22-06-16Result of AGMRNS
20-05-16Shares Magazine Investor Evening PresentationRNS
22-04-16OXP to exhibit at the Master Investor Show 2016RNS
22-04-16Oxford Pharmascience Group plc - Company updateBRR Media
19-04-16Positive Regulatory Advice from MHRARNS

RSS feeds

  • Editorial news feed for LSE:OXP Editorial
  • Regulatory news feed for LSE:OXP Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account